Clinical Trial Results:
A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to sitagliptin and placebo in patients with type 2 diabetes
mellitus inadequately controlled with metformin.
Estudio multicéntrico, randomizado, doble ciego, con doble enmascaramiento, controlado frente a placebo y a un comparador activo para evaluar la eficacia, seguridad y tolerancia de taspoglutida (RO5073031) comparado con sitagliptina y placebo en pacientes con diabetes mellitus tipo 2 controlados inadecuadamente con metformina.
Summary
|
|
EudraCT number |
2008-001854-42 |
Trial protocol |
ES FR SK DK SE GB DE GR |
Global completion date |
02 Mar 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
20 Jul 2016
|
First version publication date |
20 Jul 2016
|
Other versions |
|
Summary report(s) |
BC21713_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.